Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
778.61-
QQQ
733.62-
BTC/USD
62652.321.2188%
DIA
537.23-
GLD
402.20-
TLT
82.25-

Bicara Therapeutics Inc

BCAXNASDAQ
Trade with Public
Trade with Public
$23.75
0.120.51%
Last update: Aug 14, 8:10 AM
Earnings: Q2 2026 Earnings were released on Tue Aug 11th, before the market open
Conference Call: The most recent conference call started at 8:30 AM, 3 days ago
Click to view the webcast
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Bicara Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bicara Therapeutics (BCAX).

Price Target Range — 8 Quarters

Analyst Consensus — 13 Analysts

1S.Buy
10Buy
2Hold
Consensus RatingBuy# Analysts13Avg. Consensus PT$32Upside to Avg. PT+36.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026Goldman Sachs Richard LawPT RaiseNeutral$18→$20
Aug 12, 2026WedbushDavid NierengartenPT RaiseOutperform$30→$33
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
Benzinga Newsdesk

PRO
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
Benzinga Newsdesk

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Avi Kapoor

PRO
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $16 to $23.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved